2158 studies found for:    Immunodeficiency
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Early Diagnosis and Stem Cell Transplantation for Severe Immunodeficiency Diseases
Condition: Severe Immunodeficiency Diseases
Intervention: Drug: Fludarabine, Busulfan, and Anti-Thymocyte Globulin
2 Completed
Has Results
Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.
Conditions: Primary Immunodeficiency;   Common Variable Hypogammaglobulinemia;   X-linked Hypogammaglobulinemia;   Hypogammaglobulinemia;   Immunodeficiency With Hyper-IgM;   Wiskott-Aldrich Syndrome
Intervention: Biological: Gammaplex (Intravenous immunoglobulin)
3 Enrolling by invitation Clinical and Laboratory Online Patient- and Research Database for Primary Immunodeficiencies in Switzerland
Condition: Primary Immunodeficiency Disease
Intervention:
4 Terminated
Has Results
Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders
Conditions: Severe Combined Immunodeficiency Disease;   Severe Primary Immunodeficiency Disorder;   Undefined T Cell Deficiency Disorder;   Wiskott-Aldrick Syndrome
Interventions: Biological: Campath -1H;   Drug: Fludarabine;   Biological: Anti-CD45;   Procedure: Stem cell infusion
5 Recruiting Genetic Basis of Immunodeficiency
Condition: Severe Combined Immunodeficiency
Intervention:
6 Completed Feasibility of a Stigma Reduction Intervention for Human Immunodeficiency Virus (HIV)-Infected Women
Conditions: Human Immunodeficiency Virus (HIV);   Self-efficacy;   Self-esteem
Intervention: Behavioral: Ipod video
7 Completed Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
Conditions: Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS);   Human Immunodeficiency Virus Infections
Interventions: Drug: Serostim®;   Drug: Placebo
8 Completed An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome
Conditions: Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS);   Human Immunodeficiency Virus Infections
Intervention: Drug: Serostim®
9 Suspended Pharmacokinetics (PK) and Safety of Subgam®VF in Primary Immunodeficiency Diseases
Conditions: Primary Immune Deficiency Disorders;   Common Variable Immunodeficiency;   X-linked Agammaglobulinaemia;   Hyper-Immunoglobulin M (IgM0Syndrome
Intervention: Biological: Subgam
10 Not yet recruiting Novel Testing Procedures
Condition: Immunodeficiencies
Intervention:
11 Completed
Has Results
Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency
Conditions: Common Variable Immunodeficiency;   Agammaglobulinemia
Intervention: Drug: Vivaglobin
12 Unknown  Lymphocyte Immunophenotyping in Common Variable Immunodeficiency
Conditions: Common Variable Immunodeficiency;   Granulomatous Disease;   Bronchiectasis;   Immunoglobulin Treatment
Intervention:
13 Enrolling by invitation Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
Conditions: Lymphohistiocytosis, Hemophagocytic;   Common Variable Immunodeficiency;   Severe Combined Immunodeficiency
Intervention:
14 Recruiting Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
Conditions: X-linked Severe Combined Immunodeficiency;   XSCID;   SCID-X1;   Gamma C-Deficient SCID
Interventions: Other: Gene-modified CD34+ Hematopoietic stem cells;   Drug: Busulfan
15 Active, not recruiting Gene Therapy for X-linked Severe Combined Immunodeficiency
Condition: X-linked Severe Combined Immunodeficiency
Intervention: Other: Gene transfer
16 Not yet recruiting ASIS for GAMMAGARD in Primary Immunodeficiency
Condition: Primary Immunodeficiency
Interventions: Drug: Gadolinium For abdomen;   Drug: Gadolinium For lower back;   Drug: Efficacy of Gammagard subcutaneously at Week 12;   Drug: Efficacy of Gammagard subcutaneously at Week 24;   Drug: Efficacy of Gammagard subcutaneously at Week 36;   Drug: Efficacy of Gammagard subdermally at Week 36;   Drug: Efficacy of Gammagard subdermally at Week 12;   Drug: Efficacy of Gammagard subdermally at Week 24;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 12;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 24;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 36;   Drug: Adverse Reactions of Gammagard subdermally at Week 12;   Drug: Adverse Reactions of Gammagard subdermally at Week 24;   Drug: Adverse Reactions of Gammagard subdermally at Week 36
17 Completed Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)
Conditions: Agammaglobulinemia;   IgG Deficiency;   Common Variable Immunodeficiency
Intervention: Drug: Immunoglobulins Intravenous (Human)
18 Withdrawn A Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (HIV-1) Infection in Filipino Patients
Condition: Human Immunodeficiency Virus-Type 1
Intervention: Drug: No intervention
19 Not yet recruiting Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China
Condition: Severe Combined Immunodeficiency
Intervention: Genetic: gene sequencing
20 Completed Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
Conditions: Agammaglobulinemia;   IgG Deficiency;   Common Variable Immunodeficiency
Intervention: Drug: Immunoglobulins Intravenous (Human)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years